论文部分内容阅读
目的观察甘精胰岛素和复方甲亢片联合治疗糖尿病合并甲亢患者的临床疗效及对血糖水平的影响。方法选取医院收治的糖尿病合并甲亢患者128例,依据临床治疗方案不同分为对照组和观察组,每组64例。对照组单纯行甘精胰岛素治疗,观察组采用甘精胰岛素联合复方甲亢片治疗,观察比较2组疗效性指标(包括血糖达标时间、胰岛素用量及住院时间)与治疗前后甲状腺指标[游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)、促甲状腺激素(TSH)]变化情况。结果观察组血糖达标时间及住院时间短于对照组,胰岛素用量少于对照组(P均<0.01)。治疗前,2组FT3、FT4、TSH数值比较差异均无统计学院意义(P>0.05);治疗后,2组FT3、FT4数值较治疗前均降低,TSH数值较治疗前升高,且观察组降低或升高幅度大于对照组(P均<0.01)。结论糖尿病合并甲亢患者行甘精胰岛素和复方甲亢片联合治疗可取得显著效果,具有临床推广应用价值。
Objective To observe the clinical efficacy of insulin glargine combined with compound hyperthyroidism in the treatment of diabetic patients with hyperthyroidism and its effect on blood glucose. Methods A total of 128 patients with diabetes mellitus complicated with hyperthyroidism admitted to the hospital were selected and divided into control group and observation group according to different clinical treatment plans, with 64 cases in each group. The patients in the control group were treated with insulin glargine only. The observation group was treated with insulin glargine combined with compound hyperthyroidism tablets. The curative effect indexes (including the time of blood glucose, insulin dosage and hospital stay) of the two groups were compared with thyroid indicators [free triiodothyronine (FT3), free thyroxine (FT4), thyroid stimulating hormone (TSH)] changes. Results The observation group had shorter blood glucose time and hospital stay than the control group, with less insulin than the control group (all P <0.01). Before treatment, there was no significant difference in FT3, FT4 and TSH between the two groups (P> 0.05). After treatment, the values of FT3 and FT4 in both groups were lower than those before treatment, and TSH values were higher than those before treatment Reduce or increase more than the control group (P <0.01). Conclusion Patients with diabetes mellitus and hyperthyroidism combined with glargine and compound Hyperthyroidism tablets can achieve a significant effect, which has clinical application value.